RxDoctor Payments Data

Margaret Cooper

Adult Health · Jonesboro, ARNPI 1750305702

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.

$3,258in general payments, 2019–2025

Across 190 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$753
  • Pfizer$689
  • Abbott$428
  • Boehringer Ingelheim$196
  • Novo Nordisk$195
  • AstraZeneca$159
  • plus $838 from 16 others

What the payments were for

  • Food & beverage$3,19898%
  • Education$602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,258 in reported general payments places this provider in the 80th percentile of 154 adult health providers in Arkansas.

See all adult health providers in Arkansas

Medicare billing

Part B allowed, 2024
$89,409
Medicare patients
660
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban299$221,792
EntrestoSacubitril/Valsartan79$59,517
JardianceEmpagliflozin33$19,994
XareltoRivaroxaban25$17,226
Repatha SureclickEvolocumab16$14,452
BrilintaTicagrelor30$14,286
Rosuvastatin Calcium339$3,196
Metoprolol Succinate204$2,863
Ranolazine ErRanolazine40$2,691
Losartan Potassium166$2,346
Ezetimibe118$1,758
Flecainide Acetate55$1,581
Atorvastatin Calcium171$1,448
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$1,385
Potassium Chloride116$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$689$221,792299 claims
NovartisEntresto$753$59,51779 claims
Boehringer IngelheimJardiance$196$19,99433 claims
Johnson & JohnsonXarelto$122$17,22625 claims
AstraZenecaBrilinta$159$14,28630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 adult health providers in Arkansas.

Other adult health in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →